Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of mepolizumab for severe life-threatening or seriously debilitating asthma
NL-OMON44315Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in asthma, sponsored by GSK. Started Jul 2014; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON44315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44315.